Cancer & Oncology
Palliative evidence is strong; anti-tumor claims are not
Cannabis in oncology spans two very different evidence landscapes: palliative applications (pain, nausea, appetite) have substantial clinical evidence, while anti-tumor claims circulating online are based almost entirely on preclinical cell and animal studies that have not translated to human trials.
What the Research Shows
The palliative evidence base for cannabinoids in cancer is among the strongest in the field. Dronabinol (synthetic THC) and nabilone are FDA-approved for chemotherapy-induced nausea and vomiting (CINV) and cancer-related anorexia. Nabiximols (Sativex) has the most robust RCT evidence for cancer pain. For CINV, cannabinoids are generally considered second-line agents — effective when first-line antiemetics fail, but not superior to modern 5-HT3 antagonists as monotherapy. The anti-tumor narrative is more complex. Cannabinoids do induce apoptosis and inhibit proliferation in cancer cell lines and animal models across multiple tumor types. However, these effects occur at concentrations far higher than achievable in humans, and some studies show paradoxical pro-tumor effects at lower concentrations. No human RCTs have demonstrated anti-tumor efficacy. Patients should be counseled that cannabis cannot treat cancer, but may meaningfully improve quality of life during treatment.
Key Findings
Cannabinoids are FDA-approved for CINV
Well-StudiedDronabinol and nabilone are approved second-line antiemetics for chemotherapy-induced nausea and vomiting.
THC:CBD reduces cancer pain vs. placebo
Well-StudiedMultiple RCTs of nabiximols show significant pain reduction in cancer patients with inadequate opioid response.
Anti-tumor effects in cell lines — not humans
Limited EvidenceCannabinoids induce apoptosis in cancer cell lines, but at concentrations not achievable in vivo. No human RCT evidence.
Cannabis may improve cancer-related appetite
Emerging ResearchTHC stimulates appetite via CB1 receptors, but evidence for meaningful weight gain in cancer cachexia is limited.
Featured Studies
View all in libraryCommon Questions
What We Still Don't Know
These are open research questions — areas where the evidence is insufficient or actively contested.
- 1Can cannabinoids enhance the efficacy of chemotherapy or immunotherapy?
- 2Do cannabinoids affect cancer immunosurveillance through CB2 receptor modulation?
- 3What is the optimal cannabinoid formulation for cancer pain refractory to opioids?
- 4Does cannabis use affect cancer prognosis or survival outcomes?
- 5Can cannabinoids reduce cancer treatment-related peripheral neuropathy?